Back to Search
Start Over
Supplementary Table 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- PDF file - 77KB, Supplementary Table 1. Adverse Events that Occurred in ≥10% of Patients.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....0372b8e125d17d87c9126d948eb2e2bb